

December 19, 2024

VIA EMAIL

Sarah Bartelmann, MPH
Cost Programs Manager
Oregon Health Authority

Re: Proposed Order Suspending Transaction Review

Sarah,


We are in receipt of the proposed order, dated December 13, 2024, that would suspend the transaction between UnitedHealth Group (“UHG”) and Amedisys, Inc. (the “Proposed Order”). We understand that the Oregon Health Authority (“OHA”) is taking the position that such suspension is necessary in light of the allegations in a recent federal antitrust complaint asserting that the UGH-Amedisys transaction is unlawful.

As discussed on our December 17 call, UHG respectfully submits that such suspension is unnecessary. UHG is eager to alleviate any concerns that OHA may have about how the allegations contained in the federal antitrust complaint affect Oregon. Moreover, we are confident that the parties can agree on a set of conditions that would allow OHA to approve this transaction conditioned on the federal antitrust suit being resolved in a manner that permits the proposed transaction to close.

We therefore propose and request that OHA extend the deadline for UHG to request a contested case hearing regarding the Proposed Order until January 31, 2025, during which time the Proposed Order would not be in effect. Further, we propose and request that UHG and OHA mutually agree to toll the review period from the date of this letter to January 31, 2025.

The parties to this transaction remain committed to working collaboratively with OHA to demonstrate the benefits of this transaction to all Oregonians. Given the time-sensitive nature of this request and the upcoming holidays, we would appreciate a written reply by Monday, December 23.

Regards,



Timothy Hatfield